


**Patent claims****1. A compound of formula**

wherein

$R_1$  is  $(C_{1-4})$ alkyl,

$R_2$  is unsubstituted  $(C_{1-4})$ alkyl or  $(C_{1-4})$ alkyl substituted by unsubstituted or substituted

-  $(C_{6-18})$ aryl or

-  $(C_{6-18})$ aryl annelated with heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, S,

$R_3$  is  $(C_{6-18})$ aryl one or morefold substituted by

- halogen,

- halo( $C_{1-6}$ )alkyl,

- halo( $C_{1-6}$ )alkoxy,

- cyano,

- phenyl,

- heterocyclyl having 5 to 6 ring members and 1 to 4 heteroatoms selected from N, O, S.

**2. A compound of claim 1 wherein**

$R_1$  is methyl,

$R_2$  is methyl or

methyl substituted by

- quinolinyl,

- benzo[1,3]dioxolyl,

- phenyl


- phenyl one or morefold substituted by halogen, halo( $C_{1-4}$ )alkyl,  $(C_{1-4})$ alkoxy, cyano, amino, dimethylamino, carboxy( $C_{1-2}$ )alkylcarbonylamino, amino( $C_{1-2}$ )alkylcarbonylamino,  $(C_{2-4})$ alkylenecarbonylamino,

heterocyclcarbonyl(C<sub>1-2</sub>)alkylcarbonylamino, wherein heterocycl has 6 ring members and 2 heteroatoms selected from N, O,

- R<sub>3</sub> is phenyl one or morefold, e.g. 1- to 3-fold, substituted by

- halogen,
- halo(C<sub>1-2</sub>)alkyl,
- halo(C<sub>1-2</sub>)alkoxy,
- cyano,
- phenyl,
- heterocycl, including aromatic, having 6 ring members and 2 nitrogen heteroatoms.

3. A compound of claim 1 or 2 of formula



4. A compound of any one of claims 1 to 3 in the form of a salt.

5. A compound of formula I according to any one of claim 1 to 4 for use as a pharmaceutical.

6. The use of a compound of any one of claims 1 to 4 for the manufacture of a medicament for the treatment of disorders or diseases mediated by LFA-1/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions.

7. A pharmaceutical composition comprising a compound of formula I according to any one of claim 1 to 4 in association with at least one pharmaceutical excipient.

8. A pharmaceutical composition according to claim 7, further comprising another pharmaceutically active agent.

- 38 -

9. A method for treatment of disorders or diseases mediated by LFA-1/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I according to any one of claims 1 to 4.
10. A method according to claim 9, wherein a compound of any one of claims 1 to 4 is administered in combination with another pharmaceutically active agent, either simultaneously or in sequence.

IL/12-Dec-2003